AU2012313960B2 - Use of non-subtype B gag proteins for lentiviral packaging - Google Patents

Use of non-subtype B gag proteins for lentiviral packaging Download PDF

Info

Publication number
AU2012313960B2
AU2012313960B2 AU2012313960A AU2012313960A AU2012313960B2 AU 2012313960 B2 AU2012313960 B2 AU 2012313960B2 AU 2012313960 A AU2012313960 A AU 2012313960A AU 2012313960 A AU2012313960 A AU 2012313960A AU 2012313960 B2 AU2012313960 B2 AU 2012313960B2
Authority
AU
Australia
Prior art keywords
vector
subtype
hiv
packaging
lentiviral
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2012313960A
Other languages
English (en)
Other versions
AU2012313960A1 (en
Inventor
Cecile Bauche
Pierre Charneau
Thi-Lan TRAN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Theravectys SA
Institut Pasteur
Original Assignee
Theravectys SA
Institut Pasteur
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47522726&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2012313960(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Theravectys SA, Institut Pasteur filed Critical Theravectys SA
Publication of AU2012313960A1 publication Critical patent/AU2012313960A1/en
Application granted granted Critical
Publication of AU2012313960B2 publication Critical patent/AU2012313960B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16051—Methods of production or purification of viral material
    • C12N2740/16052—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
AU2012313960A 2011-09-26 2012-09-25 Use of non-subtype B gag proteins for lentiviral packaging Active AU2012313960B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP11306222 2011-09-26
EP11306222 2011-09-26
PCT/IB2012/002363 WO2013046034A2 (en) 2011-09-26 2012-09-25 Use of non-subtype b gag proteins for lentiviral packaging

Publications (2)

Publication Number Publication Date
AU2012313960A1 AU2012313960A1 (en) 2014-04-10
AU2012313960B2 true AU2012313960B2 (en) 2016-05-12

Family

ID=47522726

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2012313960A Active AU2012313960B2 (en) 2011-09-26 2012-09-25 Use of non-subtype B gag proteins for lentiviral packaging

Country Status (14)

Country Link
US (2) US9752160B2 (enExample)
EP (1) EP2761011B1 (enExample)
JP (3) JP6495653B2 (enExample)
KR (1) KR101811736B1 (enExample)
CN (2) CN107858375A (enExample)
AU (1) AU2012313960B2 (enExample)
BR (1) BR112014007027A2 (enExample)
CA (2) CA2959867C (enExample)
DK (1) DK2761011T3 (enExample)
ES (1) ES2683820T3 (enExample)
IL (1) IL231666B (enExample)
SG (1) SG11201400987QA (enExample)
WO (1) WO2013046034A2 (enExample)
ZA (1) ZA201401780B (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2913854A1 (en) 2013-06-03 2014-12-11 Theravectys Lentiviral vectors containing an mhc class i, mhc class ii, or beta-2 microglobulin upstream promoter sequence
WO2015063706A1 (en) * 2013-10-31 2015-05-07 Theravectys Lentiviral vectors for expression of hiv-1 antigens
EP3009144A1 (en) * 2014-10-15 2016-04-20 Theravectys Lentiviral vectors for inducing CD4+ and CD8+ immune responses in vaccination of humans
WO2016120489A2 (en) * 2015-02-01 2016-08-04 Theravectys Lentiviral vectors for expression of mycobacterium tuberculosis antigens
US12084674B2 (en) * 2019-10-07 2024-09-10 University Of Utah Research Foundation Methods and compositions for a HIV based delivery system
US20250319173A1 (en) * 2021-03-12 2025-10-16 Institut Pasteur Lentiviral vectors targeting antigens to mhc-ii pathway and inducing protective cd8+ and cd4+ t-cell immunity in a host
CN114107393A (zh) 2021-04-07 2022-03-01 上海劲威生物科技有限公司 一种治疗乙型肝炎的慢病毒载体、慢病毒颗粒及其制备方法和应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990013630A1 (fr) * 1989-05-03 1990-11-15 Institut National De La Sante Et De La Recherche Medicale (Inserm) Retrovirus hautement cytopathogenique hiv-ndk, fragments d'adn de ce retrovirus, procede de preparation d'une proteine et/ou enzyme de ce virus et leurs utilisations

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA68327C2 (en) * 1995-07-04 2004-08-16 Gsf Forschungszentrum Fur Unwe A recombinant mva virus, an isolated eukaryotic cell, infected with recombinant mva virus, a method for production in vitro of polypeptides with use of said cell, a method for production in vitro of virus parts (variants), vaccine containing the recombinant mva virus, a method for immunization of animals
US7262049B2 (en) * 1999-03-16 2007-08-28 Dana-Farber Cancer Institute, Inc. Pseudotyped lentiviral vectors and uses thereof
EP1610816B1 (en) * 2003-03-28 2013-01-02 GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Mva virus expressing modified hiv envelope, gag, and pol genes
GB0318704D0 (en) * 2003-08-08 2003-09-10 Sirus Pharmaceuticals Ltd Chimaeric vector system
CA2539021A1 (en) 2003-09-15 2005-03-31 Chiron Corporation Combination approaches for generating immune responses
GB0702694D0 (en) * 2007-02-12 2007-03-21 Ark Therapeutics Ltd Vectors
CN101353667B (zh) * 2008-08-15 2011-06-08 中国人民解放军军事医学科学院微生物流行病研究所 Hiv毒株耐药表型分析细胞模型及其专用假型慢病毒

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990013630A1 (fr) * 1989-05-03 1990-11-15 Institut National De La Sante Et De La Recherche Medicale (Inserm) Retrovirus hautement cytopathogenique hiv-ndk, fragments d'adn de ce retrovirus, procede de preparation d'une proteine et/ou enzyme de ce virus et leurs utilisations

Also Published As

Publication number Publication date
BR112014007027A2 (pt) 2017-04-11
CA2959867C (en) 2020-04-28
CN107858375A (zh) 2018-03-30
KR101811736B1 (ko) 2017-12-22
JP2017018132A (ja) 2017-01-26
ES2683820T3 (es) 2018-09-28
IL231666B (en) 2018-03-29
WO2013046034A3 (en) 2013-05-30
WO2013046034A2 (en) 2013-04-04
ZA201401780B (en) 2015-09-30
JP6495653B2 (ja) 2019-04-03
JP2014530000A (ja) 2014-11-17
CN104039968A (zh) 2014-09-10
EP2761011A2 (en) 2014-08-06
AU2012313960A1 (en) 2014-04-10
KR20140116053A (ko) 2014-10-01
US9752160B2 (en) 2017-09-05
HK1200870A1 (en) 2015-08-14
JP2018183165A (ja) 2018-11-22
CA2849652A1 (en) 2013-04-04
CA2849652C (en) 2017-11-21
NZ622860A (en) 2016-05-27
EP2761011B1 (en) 2018-05-23
CA2959867A1 (en) 2013-04-04
US20170362607A1 (en) 2017-12-21
IL231666A0 (en) 2014-05-28
US20140234908A1 (en) 2014-08-21
CN104039968B (zh) 2018-10-26
SG11201400987QA (en) 2014-07-30
DK2761011T3 (en) 2018-08-27

Similar Documents

Publication Publication Date Title
US20170362607A1 (en) Use of non-subtype b gag proteins for lentiviral packaging
Di Nunzio et al. HIV-derived vectors for therapy and vaccination against HIV
US20220204946A1 (en) Modified envelope glycoproteins for retroviridae viral vector pseudotyping and process for obtaining it
US7090837B2 (en) Compositions and methods for tissue specific targeting of lentivirus vectors
US20150182617A1 (en) Glycoproteins for pseudotyping lentivectors
Takeuchi et al. Sensitization of rhabdo-, lenti-, and spumaviruses to human serum by galactosyl (alpha1-3) galactosylation
Negre et al. Lentiviral vectors derived from simian immunodeficiency virus
Pandya et al. Development of an Rev-independent, minimal simian immunodeficiency virus-derived vector system
US9840720B2 (en) Materials and methods relating to packaging cell lines
Pandya et al. Lentivirus and foamy virus vectors: novel gene therapy tools
Mautino et al. Inhibition of HIV-1 replication by novel lentiviral vectors expressing transdominant Rev and HIV-1 env antisense
Spirin et al. Lentiviral vectors
HK1200870B (en) Use of non-subtype b gag proteins for lentiviral packaging
NZ622860B2 (en) Use of non-subtype b gag proteins for lentiviral packaging
WO2001092506A1 (en) Siv derived lentiviral vector systems
Follenzi et al. HIV-based vectors
Brady et al. High-Titer Human Immunodeficiency Virus
Dubois et al. Development of Minimal Lentivirus Vectors

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)